Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Operations (2020 - 2025)

Mirum Pharmaceuticals has reported Cash from Operations over the past 6 years, most recently at 6067000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 6067000.0 for Q4 2025, up 219.71% from a year ago — trailing twelve months through Dec 2025 was 55827000.0 (up 440.7% YoY), and the annual figure for FY2025 was 55827000.0, up 440.7%.
  • Cash from Operations for Q4 2025 was 6067000.0 at Mirum Pharmaceuticals, down from 39681000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for MIRM hit a ceiling of 39681000.0 in Q3 2025 and a floor of 40199000.0 in Q2 2021.
  • Median Cash from Operations over the past 5 years was 17776000.0 (2023), compared with a mean of 12884300.0.
  • Biggest five-year swings in Cash from Operations: tumbled 136.55% in 2021 and later skyrocketed 896.01% in 2025.
  • Mirum Pharmaceuticals' Cash from Operations stood at 33147000.0 in 2021, then decreased by 3.39% to 34270000.0 in 2022, then soared by 51.51% to 16618000.0 in 2023, then soared by 69.5% to 5068000.0 in 2024, then soared by 219.71% to 6067000.0 in 2025.
  • The last three reported values for Cash from Operations were 6067000.0 (Q4 2025), 39681000.0 (Q3 2025), and 12040000.0 (Q2 2025) per Business Quant data.